Breast Cancer SurgeryNCT06642142
Onset of Sensory Block After Thoracic ESP Block
An observational study of Breast Cancer Surgery and ESPB, run by Ospedale Santa Maria Goretti at 1 site in Italy.
Trial summary
The goal of this observational study is to to evaluate the changes in cold sensitivity and the onset of sensory block after performing a thoracic ESP block. It reflects the time it takes for the local anaesthetic to spread into the paravertebral space leading to changes in cold sensitivity in the chest. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer Surgery, ESPB
- What is being tested?
- ESP block
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 7 Nov 2024to Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients undergoing ESP block for simple quadrantectomy and partial resection with or without lymphnode resection
Who may be able to join
- Age ≥ 18 years.
- ASA score I-II-III.
- Schedule of breast surgery
- Schedule of ESPB
- Consent to the study
Who cannot join
- Allergy to local anaesthetics
- Cardiopathies, nephropathies, hepatopathies, central or peripheral neuropathies uncompensated
- Infection at the injection site
- Uncooperative patient
- BMI < 20, > 40
- Difficulty in visualising target structures or the LA spread (failure of technique)
- Pregnancy status
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Ospedale Santa Maria Goretti, Via Lucia Scaravelli
Latina, Italy, 04100
Irene Lupelli, MD, +39 3497772231, irene.lupelli@gmail.com
Giorgio Panfili, MD, + 39 3201876689, giorgio.panfili91@gmail.com
About this study
Official title: Evaluation of the Onset and the Extent of Sensory Block After Thoracic ESP Block in Breast Surgery - a Prospective Observational Study
The goal of this observational study is to to evaluate the changes in cold sensitivity and the onset of sensory block after performing a thoracic ESP block. It reflects the time it takes for the local anaesthetic to spread into the paravertebral space leading to changes in cold sensitivity in the chest.
The study population are patients undergoing simple quadrantectomy or partial resection with or without sentinel lymphnode removal, in the operating rooms of Santa Maria Goretti Hospital in Latina.
Read more
This study is observational because it simply describes and records the effects of a procedure (the ESP block) on treated patients during a period of observation.
Before surgery, unilateral thoracic ESP block (T4 level) with a sterile, ultrasound-guided technique will be performed. A timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block up to 40 minutes or until induction of general anaesthesia, the cold sensitivity of the chest will be explored.
Read the detailed description
Breast cancer is the most frequent cancer pathology in women, accounting for 30% of all cancer pathology in women in Italy. Treatment depends on the stage at diagnosis and the histotype, but the surgical approach remains the cornerstone of treatment with radical intent.
Ensuring adequate analgesia during breast surgery can be difficult due to the extensive nature of the surgery and the complex innervation of the breast.
The breast is a subcutaneous organ that receives innervation from the anterior and lateral cutaneous branches of the intercostal nerves T2 to T5 (with varying contributions from T1, T6 and T7) and the supraclavicular nerves from the cervical plexus (C3-C5). The anterior cutaneous branches of the intercostal nerves T2 to T5 cross the pectoralis major muscle near the sternum to innervate the medial quadrants of the breast. The supraclavicular nerves cross the clavicle and innervate the skin below the clavicle and part of the upper pole of the breast. The lateral skin branches of the intercostal nerves from T2 to T5 further divide into anterior and posterior divisions, which perforate the serratus muscle. The anterior divisions provide innervation to the lateral quadrants of the breast. The posterior divisions penetrate the subcutaneous tissue to innervate the lateral thoracic wall. The lateral cutaneous branch of T2 gives rise to the intercostobrachial nerve, which innervates the axilla and the medial upper arm. The first intercostal nerve rarely gives off a lateral cutaneous branch. The lateral and anterior branches of the different intercostal nerves frequently communicate with each other along their course, producing a highly variable pattern of innervation that does not adhere to the rigid dermatomeric segmentation.
Adequate pain control during and after breast surgery improves functional recovery and helps prevent the development of chronic post-operative pain.
Several neuroaxial and regional anaesthesia techniques have been proposed and studied for perioperative pain control.
The paravertebral block (PVB) is considered the gold standard; however it is a complex technique due to its anatomical proximity to the pleura and the central neuroaxial system and is therefore burdened by complications such as pneumothorax and intrathecal local anaesthetic spread.
The erector spinae plane block (ESPB) is a valid alternative to the PVB with characteristics of greater safety and ease of execution but with similar efficacy.
It consists of an ultrasound-guided injection of local anaesthetic (LA) into the virtual fascial plane between the tips of the vertebral transverse processes and the erector spinae muscles.
Depending on the vertebral level chosen, it is indicated for the (uni- or bilateral) analgesia of the thoraco-abdominal wall in various clinical contexts: thoracic surgery, breast surgery, rib fractures, chronic neuropathic pain, abdominal surgery, urological and gynaecological surgery, but also pelvic and knee surgery.
The patient is asked to assume the sitting position; vital parameters are monitored and a thorough skin disinfection is performed. The high-frequency linear probe (5-15 Hz), covered with a sterile sheath, is placed in sagittal paramedian orientation, approximately 2 cm lateral to the spinous process of the fourth thoracic vertebra. It is slid horizontally until the tip of the transverse process is identified and superficially to it the three muscle layers (from surface to depth): trapezius muscle, great rhomboid muscle and the erector muscles of the spine. A 20-gauge, 50-mm-long needle is inserted in plane until it reaches the transverse process, always keeping the structures under ultrasound vision.
After confirming the proper position of the needle tip with the administration of 0.5-1 ml of sterile saline solution, 20-30 ml of local anaesthetic is injected to perform the block. The LA spreads within this virtual plane, up to 3-6 vertebral levels in both cranial and caudal directions; the mediolateral extension is usually confined to the limits of the spinal erector muscle, given by its attachment to the costal angle and the thoracolumbar fascia.
The success of the ESPB mainly depends on a 'paravertebral by proxy' mechanism, i.e. the diffusion of the local anaesthetic in the paravertebral space, through the superior costo-transverse ligaments or through the costo-transverse foramen. In the paravertebral space the LA reaches and wets the spinale nerve roots, determining the effect of the ESPB.
However, it is not known how long it takes for this to occur, i.e. the onset of the blockade and how long the anaesthetic continues to spread in the paravertebral space allowing an increase in the affected dermatomeres is currently unknown in the literature. Knowing this timeframe could be useful and helpful in assessing the minimum time required to ensure adequate onset of analgesia after the technique has been performed.
The aim of the study is to assess the extent of sensory changes, described through altered cold sensitivity, after ESPB at the level of the thoracic skin as time passes. The onset of the sensory changes and the extent of anaesthesia on the thoracic dermatomeres indirectly represent the time required for the LA to reach anteriorly the paravertebral space and wet the spinal nerve roots.
The study population are patients undergoing simple quadrantectomy and partial resection with or without lymphnode resection, in the operating rooms of Santa Maria Goretti Hospital in Latina. Each patient will be enrolled after verification of inclusion/exclusion requirements and collection of written informed consent.
Inclusion criteria are
- Age ≥ 18 years.
- ASA score I-II-III.
- Schedule of breast surgery
- Schedule of ESPB
- Consent to the study Exclusion criteria
- Allergy to local anaesthetics
- Cardiopathies, nephropathies, hepatopathies, central or peripheral neuropathies uncompensated
- Infection at the injection site
- Uncooperative patient
- BMI < 20, > 40
- Difficulty in visualising target structures or the LA spread (failure of technique)
- Pregnancy status
The study has been designed as prospective, single-centre, observational. Perioperative data collection will begin upon patient arrival in the operating room and end at the conclusion of surgery.
The study will end after one year or when the planned sample size is reached. Since this is a prospective observational study of an exploratory nature, there are no previous case histories, and involves no additional risk for patients, there is no need for an a priori sample size calculation. An a priori sample size of 30 patients was therefore established.
Patients who are candidates for breast surgery will undergo a standard anaesthesiological evaluation during which their eligibility for the study will be assessed.
As per the standardised procedure, all patients will be informed about the planned anaesthesia technique and will be asked for informed consent to anaesthesia, pointing out the related anaesthesia risks. Patients will then be asked if they wish to participate in the study. If so, they will be given the consent form for the study, accompanied by a full explanation. If yes, the anaesthetist will ask them to sign the informed consent form for the study. Data collected before surgery are: age, sex, weight, height, BMI, ASA score, comorbidities, surgery history.
On the day of surgery, upon arrival in the operating theatre, the patient will be monitored with electrocardiogram, saturimetry, non-invasive pressure. Management will follow the standard currently applied in the operating room, no changes will be made for the following study.
We briefly describe the usual care of the patient: After premedication with Midazolam 1-2 mg, ESPB will be performed with sterile us-guided technique. The block will be performed at the T4 level, monolaterally, with 30ml volume of 0.5% Ropivacaine. A timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes after the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored. Skin areas where the patient will not perceive the sensation of cold, i.e. anaesthetised skin dermatomeres, will be reported on a schematic template attached to each patient's data collection sheet.
Participation in the study will not lead to changes in clinical practice and all interventions will follow usual care. Procedures will be performed under balanced general anaesthesia or intravenous anaesthesia at the attending anaesthetist'discretion.
This study does not alter commonly used anaesthetic procedures. Therefore, participation in this study will not entail any additional risk for patients and there are no direct benefit associated with it.
- Conditions
- Breast Cancer Surgery, ESPB
- Being tested
- ESP block
- Keywords
- ESPB
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ESP blockProcedure or surgery
The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure.
Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored.
What is being measured
The primary outcome is the main question the study is designed to answer.
The onset of sensory block after thoracic ESP block after one minute
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: One minute after ESPB is performed
The onset of sensory block after thoracic ESP block after three minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 3 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after five minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 5 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 10 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 10 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 15 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 15 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 20 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 20 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 25 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 25 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 30 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 30 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 35 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 35 minutes after ESPB is performed
The onset of sensory block after thoracic ESP block after 40 minutes
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Measured: 40 minutes after ESPB is performed
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start7 Nov 2024
- Primary completionOct 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast Cancer SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ospedale Santa Maria Goretti
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Irene Lupelli, Ospedale Santa Maria Goretti
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06642142
- Sponsor's protocol ID
- 2024-07-OSSSZ-6435-LUPELLI
- Status last verified
- Nov 2024
- First submitted
- 7 Oct 2024
- Last updated
- 8 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Onset and the Extent of Sensory Block After Thoracic ESP Block in Breast Surgery - a Prospective Observational Study
- ClinicalTrials.gov ID
- NCT06642142
- Acronym / sponsor ID
- 2024-07-OSSSZ-6435-LUPELLI
- Conditions
- Breast Cancer Surgery, ESPB
- Keywords
- ESPB
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Ospedale Santa Maria GorettiUniversity, hospital or other
- Study start
- 7 Nov 2024 (actual)
- Primary completion
- Oct 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to to evaluate the changes in cold sensitivity and the onset of sensory block after performing a thoracic ESP block. It reflects the time it takes for the local anaesthetic to spread into the paravertebral space leading to changes in cold sensitivity in the chest.
The study population are patients undergoing simple quadrantectomy or partial resection with or without sentinel lymphnode removal, in the operating rooms of Santa Maria Goretti Hospital in Latina.
This study is observational because it simply describes and records the effects of a procedure (the ESP block) on treated patients during a period of observation.
Before surgery, unilateral thoracic ESP block (T4 level) with a sterile, ultrasound-guided technique will be performed. A timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block up to 40 minutes or until induction of general anaesthesia, the cold sensitivity of the chest will be explored.
Detailed description
Breast cancer is the most frequent cancer pathology in women, accounting for 30% of all cancer pathology in women in Italy. Treatment depends on the stage at diagnosis and the histotype, but the surgical approach remains the cornerstone of treatment with radical intent.
Ensuring adequate analgesia during breast surgery can be difficult due to the extensive nature of the surgery and the complex innervation of the breast.
The breast is a subcutaneous organ that receives innervation from the anterior and lateral cutaneous branches of the intercostal nerves T2 to T5 (with varying contributions from T1, T6 and T7) and the supraclavicular nerves from the cervical plexus (C3-C5). The anterior cutaneous branches of the intercostal nerves T2 to T5 cross the pectoralis major muscle near the sternum to innervate the medial quadrants of the breast. The supraclavicular nerves cross the clavicle and innervate the skin below the clavicle and part of the upper pole of the breast. The lateral skin branches of the intercostal nerves from T2 to T5 further divide into anterior and posterior divisions, which perforate the serratus muscle. The anterior divisions provide innervation to the lateral quadrants of the breast. The posterior divisions penetrate the subcutaneous tissue to innervate the lateral thoracic wall. The lateral cutaneous branch of T2 gives rise to the intercostobrachial nerve, which innervates the axilla and the medial upper arm. The first intercostal nerve rarely gives off a lateral cutaneous branch. The lateral and anterior branches of the different intercostal nerves frequently communicate with each other along their course, producing a highly variable pattern of innervation that does not adhere to the rigid dermatomeric segmentation.
Adequate pain control during and after breast surgery improves functional recovery and helps prevent the development of chronic post-operative pain.
Several neuroaxial and regional anaesthesia techniques have been proposed and studied for perioperative pain control.
The paravertebral block (PVB) is considered the gold standard; however it is a complex technique due to its anatomical proximity to the pleura and the central neuroaxial system and is therefore burdened by complications such as pneumothorax and intrathecal local anaesthetic spread.
The erector spinae plane block (ESPB) is a valid alternative to the PVB with characteristics of greater safety and ease of execution but with similar efficacy.
It consists of an ultrasound-guided injection of local anaesthetic (LA) into the virtual fascial plane between the tips of the vertebral transverse processes and the erector spinae muscles.
Depending on the vertebral level chosen, it is indicated for the (uni- or bilateral) analgesia of the thoraco-abdominal wall in various clinical contexts: thoracic surgery, breast surgery, rib fractures, chronic neuropathic pain, abdominal surgery, urological and gynaecological surgery, but also pelvic and knee surgery.
The patient is asked to assume the sitting position; vital parameters are monitored and a thorough skin disinfection is performed. The high-frequency linear probe (5-15 Hz), covered with a sterile sheath, is placed in sagittal paramedian orientation, approximately 2 cm lateral to the spinous process of the fourth thoracic vertebra. It is slid horizontally until the tip of the transverse process is identified and superficially to it the three muscle layers (from surface to depth): trapezius muscle, great rhomboid muscle and the erector muscles of the spine. A 20-gauge, 50-mm-long needle is inserted in plane until it reaches the transverse process, always keeping the structures under ultrasound vision.
After confirming the proper position of the needle tip with the administration of 0.5-1 ml of sterile saline solution, 20-30 ml of local anaesthetic is injected to perform the block. The LA spreads within this virtual plane, up to 3-6 vertebral levels in both cranial and caudal directions; the mediolateral extension is usually confined to the limits of the spinal erector muscle, given by its attachment to the costal angle and the thoracolumbar fascia.
The success of the ESPB mainly depends on a 'paravertebral by proxy' mechanism, i.e. the diffusion of the local anaesthetic in the paravertebral space, through the superior costo-transverse ligaments or through the costo-transverse foramen. In the paravertebral space the LA reaches and wets the spinale nerve roots, determining the effect of the ESPB.
However, it is not known how long it takes for this to occur, i.e. the onset of the blockade and how long the anaesthetic continues to spread in the paravertebral space allowing an increase in the affected dermatomeres is currently unknown in the literature. Knowing this timeframe could be useful and helpful in assessing the minimum time required to ensure adequate onset of analgesia after the technique has been performed.
The aim of the study is to assess the extent of sensory changes, described through altered cold sensitivity, after ESPB at the level of the thoracic skin as time passes. The onset of the sensory changes and the extent of anaesthesia on the thoracic dermatomeres indirectly represent the time required for the LA to reach anteriorly the paravertebral space and wet the spinal nerve roots.
The study population are patients undergoing simple quadrantectomy and partial resection with or without lymphnode resection, in the operating rooms of Santa Maria Goretti Hospital in Latina. Each patient will be enrolled after verification of inclusion/exclusion requirements and collection of written informed consent.
Inclusion criteria are
- Age ≥ 18 years.
- ASA score I-II-III.
- Schedule of breast surgery
- Schedule of ESPB
- Consent to the study Exclusion criteria
- Allergy to local anaesthetics
- Cardiopathies, nephropathies, hepatopathies, central or peripheral neuropathies uncompensated
- Infection at the injection site
- Uncooperative patient
- BMI < 20, > 40
- Difficulty in visualising target structures or the LA spread (failure of technique)
- Pregnancy status
The study has been designed as prospective, single-centre, observational. Perioperative data collection will begin upon patient arrival in the operating room and end at the conclusion of surgery.
The study will end after one year or when the planned sample size is reached. Since this is a prospective observational study of an exploratory nature, there are no previous case histories, and involves no additional risk for patients, there is no need for an a priori sample size calculation. An a priori sample size of 30 patients was therefore established.
Patients who are candidates for breast surgery will undergo a standard anaesthesiological evaluation during which their eligibility for the study will be assessed.
As per the standardised procedure, all patients will be informed about the planned anaesthesia technique and will be asked for informed consent to anaesthesia, pointing out the related anaesthesia risks. Patients will then be asked if they wish to participate in the study. If so, they will be given the consent form for the study, accompanied by a full explanation. If yes, the anaesthetist will ask them to sign the informed consent form for the study. Data collected before surgery are: age, sex, weight, height, BMI, ASA score, comorbidities, surgery history.
On the day of surgery, upon arrival in the operating theatre, the patient will be monitored with electrocardiogram, saturimetry, non-invasive pressure. Management will follow the standard currently applied in the operating room, no changes will be made for the following study.
We briefly describe the usual care of the patient: After premedication with Midazolam 1-2 mg, ESPB will be performed with sterile us-guided technique. The block will be performed at the T4 level, monolaterally, with 30ml volume of 0.5% Ropivacaine. A timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes after the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored. Skin areas where the patient will not perceive the sensation of cold, i.e. anaesthetised skin dermatomeres, will be reported on a schematic template attached to each patient's data collection sheet.
Participation in the study will not lead to changes in clinical practice and all interventions will follow usual care. Procedures will be performed under balanced general anaesthesia or intravenous anaesthesia at the attending anaesthetist'discretion.
This study does not alter commonly used anaesthetic procedures. Therefore, participation in this study will not entail any additional risk for patients and there are no direct benefit associated with it.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing ESP block for simple quadrantectomy and partial resection with or without lymphnode resection
Key inclusion criteria (5 listed)
- Age ≥ 18 years.
- ASA score I-II-III.
- Schedule of breast surgery
- Schedule of ESPB
- Consent to the study
Key exclusion criteria (7 listed)
- Allergy to local anaesthetics
- Cardiopathies, nephropathies, hepatopathies, central or peripheral neuropathies uncompensated
- Infection at the injection site
- Uncooperative patient
- BMI < 20, > 40
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ESP blockThe ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure. Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored. | Procedure or surgery | – |
Primary outcome
The onset of sensory block after thoracic ESP block after one minute
Time frame: One minute after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after three minutes
Time frame: 3 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after five minutes
Time frame: 5 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 10 minutes
Time frame: 10 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 15 minutes
Time frame: 15 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 20 minutes
Time frame: 20 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 25 minutes
Time frame: 25 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 30 minutes
Time frame: 30 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 35 minutes
Time frame: 35 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
The onset of sensory block after thoracic ESP block after 40 minutes
Time frame: 40 minutes after ESPB is performed
Assessment of the onset, the extent and the evolution, as the time passes by, of sensory changes, described through absent or altered cold sensitivity on the thoracic dermatomeres, after performing thoracic (T4 level) ESPB.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Breast Cancer Surgery
Not yet recruiting
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
Breast Cancer, Breast Neoplasms
Active, not recruiting
The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
Recruiting
Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
Breast Cancer
RecruitingPhase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer Surgery and ESPB, run by Ospedale Santa Maria Goretti at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Irene Lupelli, MD (+39 3497772231, irene.lupelli@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The onset of sensory block after thoracic ESP block after one minute (time frame: One minute after ESPB is performed). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2024.